Over the past year, the question has been coming in from everywhere – from my patients and family members, from colleagues ...

Eli Lilly (NYSE: LLY) sells a broad range of pharmaceuticals treating various diseases, but one portfolio in particular has ...

The United Kingdom will study whether the use of weight loss drugs could get people back to work. UK Health Minister Wes ...

Lifestyle interventions that fully integrate the experiences of Black women into their treatment may produce better results.

Jim Gaffigan has a sleek new look to match his recent Hollywood renaissance, which includes his hilarious turn on SNL as vice ...

Eli Lilly's Phase 3 study shows tirzepatide significantly cuts type 2 diabetes risk and supports 22.9% average weight loss in adults over three years.

The chart below compares the forward price to earnings (P/E) ratio of AstraZeneca to multiples in a peer set of leading ...

Eli Lilly said on Wednesday its weight-loss drug helped nearly 99% of patients remain diabetes-free after three years of ...

Following an impressive data drop this summer highlighting the potential for Eli Lilly’s tirzepatide to stave off progression ...

Scientists at the University of Copenhagen have discovered a new weight loss drug target that reduces appetite, increases ...

Jim Gaffigan has always used his weight and love for eating as a punchline in his comedy, even going so far to title his 2013 ...

Right now, Eli Lilly dominates the weight loss industry thanks to its dual agonists Mounjaro and Zepbound. Viking ...